Pilot study on platelet–leukocyte aggregates (PLAs) in aortic valve disease and following transcatheter aortic valve implantation (TAVI)

Pilot study on platelet–leukocyte aggregates (PLAs) in aortic valve disease and following transcatheter aortic valve implantation (TAVI) - PLATAVI

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038888

Enrollment

Registered

2026-04-07

Start date

2026-03-07

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T82.8 I35.0

Interventions

Group 1: Arm 1: Patients with clinically relevant aortic valve disease undergoing transcatheter aortic valve implantation (TAVI), in whom platelet–leukocyte aggregates (PLAs) are assessed at predefine

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: written consent clear assignment to one of the three study groups

Exclusion criteria

Exclusion criteria: Acute systemic infection Inability to provide informed consent

Design outcomes

Primary

Measure	Time frame
Platelet–leukocyte aggregate (PLA) levels measured by flow cytometry from routine blood samples before TAVI, early after TAVI, and at approximately 30 days follow-up.	—

Secondary

Measure	Time frame
Temporal changes in PLA levels after TAVI and exploratory comparison of PLA levels between TAVI patients, patients with prosthetic valve thrombosis, and control subjects	—

Countries

Germany

Contacts

Public ContactMarc Adrian Rogmann

Universitätsmedizin Mainz - Zentrum für Kardiologie

marcadrian.rogmann@unimedizin-mainz.de+49 6131 177251

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026